Literature DB >> 12700461

Primary resistance mutations to fusion inhibitors and polymorphisms in gp41 sequences of HIV-1 non-B subtypes and recombinants.

Maria L Villahermosa1, Lucia Perez-Alvarez, Rocio Carmona, Maria T Cuevas, Migue M Thomson, Leandro Medrano, Elena Vazquez de Parga, Elena Delgado, José Domingo Pedreira, Rafael Nájera.   

Abstract

Primary resistance mutations to fusion inhibitors and polymorphisms in gp41 sequences of non-B subtypes and recombinant HIV-1 isolates were analysed. L91H to RPR103611 was detected in one DGpol/Denv/Dgp41 recombinant; L9F and K144R, rarely reported previously, were frequent in the B region of CRF14_BG recombinants. V194I and V318A, not described in the G subtype, were detected in the G region of BG recombinants and in G subtype viruses that also show the rare mutations T115L, M118V and K90R.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12700461     DOI: 10.1097/00002030-200305020-00020

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  4 in total

Review 1.  HIV-1 drug resistance mutations: an updated framework for the second decade of HAART.

Authors:  Robert W Shafer; Jonathan M Schapiro
Journal:  AIDS Rev       Date:  2008 Apr-Jun       Impact factor: 2.500

2.  Transmembrane protein polymorphisms and resistance to T-20 (Enfuvirtide, Fuzeon) in HIV-1 infected therapy-naive seroconverters and AIDS patients under HAART-T-20 therapy.

Authors:  Vladimir A Morozov; Alexei V Morozov; Dirk Schürmann; Dirck Schürmann; Heiko Jessen; Claudia Kücherer
Journal:  Virus Genes       Date:  2007-04-18       Impact factor: 2.332

Review 3.  Escape from human immunodeficiency virus type 1 (HIV-1) entry inhibitors.

Authors:  Christopher J De Feo; Carol D Weiss
Journal:  Viruses       Date:  2012-12       Impact factor: 5.048

4.  Enfuvirtide antiretroviral therapy in HIV-1 infection.

Authors:  Christina Mr Kitchen; Miriam Nuño; Scott G Kitchen; Paul Krogstad
Journal:  Ther Clin Risk Manag       Date:  2008-04       Impact factor: 2.423

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.